Ownership and insider activity for NeoGenomics, Inc. (NEO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers.
Price
| Price | $19.65 |
| Market Cap | $505M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | Olivo Alicia C | F-InKind | 2,692 | |
| 2026-08-21 | Stone Warren | M-Exempt | 28,106 | |
| 2026-08-21 | Stone Warren | F-InKind | 11,060 | |
| 2026-08-21 | Stone Warren | M-Exempt | 28,106 | |
| 2026-08-04 | Aunan Greg D | S-Sale | 20,000 | $321K |
| 2026-06-23 | Starrett Carolyn S | A-Award | 14,125 | |
| 2026-06-23 | Starrett Carolyn S | A-Award | 9,784 | $110K |
| 2026-06-23 | Starrett Carolyn S | |||
| 2026-06-15 | TETRAULT LYNN A. | S-Sale | 5,307 | $59K |
| 2026-06-09 | TETRAULT LYNN A. | S-Sale | 5,307 | $60K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.5M | $12.8M | $9.8M | $173.0M | $228.7M | $316.8M | $263.2M | $342.5M | $367.0M | $159.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | $67.5M | $198.6M | $174.8M | $72.7M | $19.8M | 0 |
| Receivables | $55.5M | $60.4M | $76.9M | $95.2M | $106.8M | $112.1M | $119.7M | $131.3M | $150.5M | $159.2M |
| Inventory | $6.3M | $7.5M | $8.7M | $14.4M | $29.5M | $23.4M | $24.3M | $24.2M | $26.7M | $28.6M |
| Total Current Assets | $78.8M | $85.0M | $103.7M | $290.7M | $448.7M | $681.5M | $605.3M | $596.8M | $596.0M | $376.3M |
| Property, Plant & Equipment | $34.0M | $36.5M | $60.9M | $90.7M | $151.9M | $211.7M | $198.6M | $183.8M | $173.7M | $163.3M |
| Goodwill | $147.0M | $147.0M | $197.9M | $198.6M | $211.1M | $527.1M | $522.8M | $522.8M | $522.8M | $524.3M |
| Intangible Assets | $77.1M | $74.2M | $140.0M | $126.6M | $120.7M | $442.3M | $408.3M | $373.1M | $339.7M | $286.5M |
| Total Assets | $337.1M | $343.3M | $505.0M | $709.5M | $988.3M | $1.87B | $1.74B | $1.68B | $1.64B | $1.36B |
| Accounts Payable | $16.8M | $10.4M | $17.8M | $19.6M | $25.0M | $17.9M | $20.5M | $20.3M | $21.6M | $23.1M |
| Short-term Debt | $3.8M | $3.8M | $14.2M | $13.8M | $2.8M | $1.1M | 0 | 0 | $200.8M | $4.8M |
| Total Current Liabilities | $59.9M | $35.1M | $60.9M | $63.9M | $73.2M | $87.2M | $89.9M | $96.3M | $301.2M | $88.3M |
| Long-term Debt | $92.1M | $91.2M | $98.1M | $91.8M | $168.1M | $532.5M | $535.3M | $538.2M | $340.3M | $404.7M |
| Total Liabilities | $150.5M | $137.8M | $184.6M | $202.1M | $294.0M | $761.5M | $742.0M | $739.7M | $735.7M | $523.3M |
| Retained Earnings | -$52.5M | -$57.5M | -$51.3M | -$11.4M | -$7.2M | -$14.8M | -$159.1M | -$247.1M | -$325.8M | -$433.8M |
| Total Equity | $186.6M | $205.5M | $320.4M | $507.4M | $694.3M | $1.11B | $998.0M | $941.5M | $902.3M | $836.6M |
| Total Debt | $106.2M | $105.4M | $112.3M | $132.9M | $218.2M | $612.8M | $610.9M | $611.7M | $605.3M | $472.3M |
| Net Debt | $93.6M | $92.6M | $102.5M | -$40.1M | -$78.0M | $97.4M | $172.9M | $196.5M | $218.5M | $312.7M |
| Working Capital | $18.9M | $49.9M | $42.7M | $226.8M | $375.5M | $594.3M | $515.4M | $500.5M | $294.8M | $288.0M |
Financial Health
| Debt / Equity | 0.57 |
| Current Ratio | 3.60 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 0.53 |
Profitability
| Return on Equity | -6.31% |
| Return on Invested Capital | -5.03% |
| Return on Assets | -3.84% |
| Gross Margin | 42.92% |
| Operating Margin | -8.63% |
| Net Margin | -6.77% |
Related companies: ACRS · ARCT · HUMA · MDXH · QTRX · SGMT · SMTI
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NEO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks